Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancer

BACKGROUND: Second‐line (2 L) chemotherapy is important for improved survival. However, the efficacy of S‐1 after nab‐paclitaxel plus gemcitabine (AG) for advanced pancreatic cancer (APC) remains unclear. AIM: We retrospectively investigated the clinical impact of S‐1 after AG. METHODS AND RESULTS:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Rep (Hoboken)
Asıl Yazarlar: Iede, Kiyotsugu, Yamada, Terumasa, Kato, Ryo, Ueda, Masami, Tsuda, Yujiro, Nakashima, Shinsuke, Ohta, Katsuya, Matsuyama, Jin, Ikenaga, Masakazu, Tominaga, Shusei
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Clinical Study Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941501/
https://ncbi.nlm.nih.gov/pubmed/32672000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1215
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller